To hear about similar clinical trials, please enter your email below
Trial Title:
Clinical Outcomes of Treatment With Immunomodulator Plus Cancer Therapies for Patients With Colorectal Cancer
NCT ID:
NCT06557668
Condition:
Colorectal Cancer
Conditions: Official terms:
Colorectal Neoplasms
Conditions: Keywords:
Colorectal Cancer
Astragalus Polysaccharides
Survival
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Retrospective
Summary:
This study aims to evaluate the survival and treatment outcomes among colorectal cancer
patients undergoing anti-cancer treatment, both with and without an immunomodulator.
Detailed description:
Colorectal cancer (CRC) is the third most common cancer worldwide. The clinical outcomes
from CRC treatments are often unsatisfactory for the majority of patients. The tumor
microenvironment (TME) plays an important role to regulate tumor growth, progression, and
metastasis and can limit the efficacy of cancer therapies. Therefore, targeting TME could
provide an efficient approach for cancer treatment.
Astragalus Polysaccharide Injection, an immunomodulator, which can stimulate medullary
hematopoiesis and enhance immune function. It also can modulate TME. Astragalus
Polysaccharide Injection has been approved as a prescription drug for alleviating
cancer-related fatigue by the Taiwan Food and Drug Administration (TFDA).
In this retrospective study, we will collect clinical data and survival status of
colorectal cancer patients undergoing anti-cancer treatment from their medical records
with and without immunomodulator, Astragalus polysaccharide Injection. It can be used to
understand the possible clinical benefit of immunomodulator plus anti-cancer therapies
for patients with colorectal cancer, and physicians can refer to these results to give
patients the suitable treatment recommendations.
Criteria for eligibility:
Study pop:
Colorectal Cancer
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Aged 20 years and older.
- Patients who have been given a diagnosis of colorectal cancer.
- Patients had previously initiated anti-cancer therapies between January 1, 2020, and
Apr 30, 2024.
Exclusion Criteria:
- None
Gender:
All
Minimum age:
20 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Chung-Shan Medical University Hospital
Address:
City:
Taichung City
Country:
Taiwan
Status:
Recruiting
Facility:
Name:
Taichung Veterans General Hospital
Address:
City:
Taichung City
Country:
Taiwan
Status:
Recruiting
Start date:
August 20, 2024
Completion date:
April 2025
Lead sponsor:
Agency:
Taichung Veterans General Hospital
Agency class:
Other
Source:
Taichung Veterans General Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06557668
